Current clinical trials in amyotrophic lateral sclerosis

被引：28

作者：

Bhatt, Jaydeep M. ^{[1
]}

Gordon, Paul H. ^{[1
]}

机构：

[1] Columbia Univ, Dept Neurol, Neurol Inst, Eleanor & Lou Gehrig MDA ALS Res Ctr, New York, NY 10032 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2007年 / 16卷 / 08期

基金：

美国国家卫生研究院;

关键词：

amyotrophic lateral sclerosis; clinical trials; excitotoxicity; minocycline; motor neuron degeneration; neuroprotective agents; neurotrophic factors; riluzole;

D O I：

10.1517/13543784.16.8.1197

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Amyotrophic lateral sclerosis is caused by selective degeneration of motor neurons in the brain and spinal cord. There are still no other effective therapies 10 years after the approval of riluzole for the treatment of amyotrophic lateral sclerosis, but advances in drug development and screening are substantially increasing the number of potential therapeutic agents. This review provides an overview of clinical trial methodology in annyotrophic lateral sclerosis followed by a systematic evaluation of drugs that are presently in Phase I, II and III clinical trials. There is an emphasis on the scientific evidence supporting the selection of each drug being tested, as well as on trial design.

引用

收藏

页码：1197 / 1207

页数：11

相关论文

共 92 条

[41] Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord [J].

Hu, JH ;

Zhang, H ;

Wagey, R ;

Krieger, C ;

Pelech, SL .

JOURNAL OF NEUROCHEMISTRY, 2003, 85 (02) :432-442

[42] Differentially expressed genes in sporadic amyotrophic lateral sclerosis spinal cords - screening by molecular indexing and subsequent cDNA microarray analysis [J].

Ishigaki, S ;

Niwa, J ;

Ando, Y ;

Yoshihara, T ;

Sawada, K ;

Doyu, M ;

Yamamoto, M ;

Kato, K ;

Yotsumoto, Y ;

Sobue, G .

FEBS LETTERS, 2002, 531 (02) :354-358

[43] Rapid communication - Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis [J].

Janson, CG ;

Ramesh, TM ;

During, MJ ;

Leone, P ;

Heywood, J .

JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2001, 10 (06) :913-915

[44]

Jewell H, 1998, CLIN PHARMACOL THER, V63, P190

[45] Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model [J].

Kaspar, BK ;

Lladó, J ;

Sherkat, N ;

Rothstein, JD ;

Gage, FH .

SCIENCE, 2003, 301 (5634) :839-842

[46] The ALSFRSr predicts survival time in an ALS clinic population [J].

Kaufmann, P ;

Levy, G ;

Thompson, JLP ;

DelBene, ML ;

Battista, V ;

Gordon, PH ;

Rowland, LP ;

Levin, B ;

Mitsumoto, H .

NEUROLOGY, 2005, 64 (01) :38-43

[47]

KAWAMATA T, 1992, AM J PATHOL, V140, P691

[48] Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice [J].

Kieran, D ;

Kalmar, B ;

Dick, JRT ;

Riddoch-Contreras, J ;

Burnstock, G ;

Greensmith, L .

NATURE MEDICINE, 2004, 10 (04) :402-405

[49] Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis [J].

Klivenyi, P ;

Kiaei, M ;

Gardian, G ;

Calingasan, NY ;

Beal, MF .

JOURNAL OF NEUROCHEMISTRY, 2004, 88 (03) :576-582

[50] Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis [J].

Klivenyi, P ;

Ferrante, RJ ;

Matthews, RT ;

Bogdanov, MB ;

Klein, AM ;

Andreassen, OA ;

Mueller, G ;

Wermer, M ;

Kaddurah-Daouk, R ;

Beal, MF .

NATURE MEDICINE, 1999, 5 (03) :347-350

← 1 2 3 4 5 6 7 8 9 10 →